In this week’s Nature, researchers from the University of Massachusetts Medical School reported on the silencing of a third copy of chromosome 21 that causes Down’s syndrome in a cell culture model of the disorder, marking a step forward towards “chromosome therapy.” The scientists used zinc finger nucleases to insert an inducible transgene version of a gene called XIST into cultured stem cells from Down’s syndrome patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Science

Ancient Wheat

Funds Needed

This Week in PNAS

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.